References
- Keating M. J., Kantarjian H., Smith T. L. Response to salvage therapy and survival after relapse in acute myeloge-nous leukemia. J Clin Oncol 1989; 7: 1071–80
- Curtis J. E., Messner H. A., Minden M. D., et al. High-dose cytosine arabinoside in the treatment of acute myel-ogenous leukemia: Contributions to outcome of clinical and laboratory attributes. J Clin Oncol 1987; 5: 532–543
- Woods W., Ruymann F., Lampkin B., et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance in therapy in the treatment of children with acute non-lymphocytic leukemia. Cancer 1990; 66: 1106–1113
- Herzig R. H., Wolf S. N., Lazarus H. M., et al. High dose cytosine therapy for refractory leukemia. Blood 1983; 62: 361–9
- Kufe D., Spriggs D. R. Biochemical and cellular pharmacology of cytosine arabinoside. Sem Oncol 1985; 12(Suppl 3)34–48
- Ochs J., Sinkule J. A., Danks M. K., et al. Continous infusion of high-dose cytosine arabinoside in refractory childhood leukemia. J Clin Oncol 1984; 2: 1092–97
- Mirro J., Hurwitz C. A., Behm F. G., et al. Effects of recombinant growth factors on leukemic blasts from children with acute myeloblastic leukemia. Leukemia 1993; 7: 1026–33
- Laver J., Duncan E., Abboud M., et al. High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. J Pediatr 1990; 116: 627–632
- Crissman H. A., Steinkamp J. A. Rapid simultaneous measurement of DNA, protein and cell volume in single cells from latge mammalian cell populations. J Cell Biol 1973; 59: 766–72
- Rosner B. Fundamentals of Biostatistics, 3rd Edition. 1990; 304–309, (PWS-Kent Publishing, Boston, MA)
- Shearer P., Katz J., Bozeman P., et al. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myel-ogenous leukemia. Cancer 1994; 74, 1953–8.
- Hakami N., Look T., Steuber C. P., et al. Combined etoposide and 5-azacytidine (5A3) in children and adolescents with refractory or relapsed acute non-lymphocytic leukemia (ANLL). J Clin Oncol 1987; 5: 1022–25
- Te Boekhorst P. A., Lowenberg B., Vlastuin M., et al. Enhanced chemosensitivity of clonogenis blasts from patients with acute myeloid leukemia by G-CSF, IL-3, or GM-CSF stimulation. Leukemia 1993; 7: 1191–8
- Bhalla K., Tourkina E., Huang Y., et al. Effect of hemopoietic growth factors G-CSF and PIXY 321 on the activity of high dose ara-C in human myeloid leukemia cells. Leuk Lymphoma 1993; 10(Suppl)123–31
- Estey E., Thall P. F., Kantarjian H., et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continous infusion high-dose ara-C+daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246–55
- Estey E., Thall P., Andreef M., et al. Use of granulocyte colony stimulating factor before, during, and after flu-darabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671–8
- Stone R. M., Berg T. D., George S. L., et al. Granulocyte-Macropbage Colony-Stimulating Factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671–7
- Lowenberg B., Van Putten W. L., Touw I. P., et al. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993; 328: 614–9